Bebe Akinboade
You Are Here

TDM1, NEW BREAST CANCER DRUG WITH LESSER SIDE EFFECT

Spread the love

T-DM1 a new drug that can sustain cancer
patients for over 30 years without effects has just been found.
T-DM1 belongs to the group of antibody drug conjugates, which seem to be the
current pulse of cancer treatment research. The toxins or medications to kill
cancer cells are linked to proteins called antibodies. These antibodies
recognize receptors on the surface of cancer cells and bind to them. Thus, when
they enter the cells, they are broken down, releasing the toxin directly into
the cancer cells. The toxins can act only once they are released into a cancer
cell and hence are not harmful to normal cells of the body.
The results of a study of an experimental drug, T-DM1, part of a new class of
cancer drugs, was presented in ASCO, Chicago, couple of weeks ago. The drug,
T-DM1, delayed breast cancer progression without many of the side effects that
usually accompany a chemotherapy treatment. The fusion drug delivers the
medication to tumor cells directly without affecting healthy cells.
T-DM1 is being developed by Genentech and will apply for FDA approval of the
same by the end of the year.

bebeakinboade
Latest posts by bebeakinboade (see all)

Related Posts